Key result
Novel antihypertensives targeting endothelin, angiotensinogen, aldosterone synthase, and ANP show promise for treatment resistance.
Why the study?
Many hypertensive patients are inadequately treated due to nonadherence, drug ineffectiveness, or counterbalancing mechanisms, and novel antihypertensive drugs have not been introduced for decades despite recent emerging compounds.
Novel antihypertensive agents targeting the endothelin system, RAAS, and ANP offer new mechanisms and longer half-lives that may improve blood pressure control and medication adherence in the future.
Treatment of hypertension generally requires multiple antihypertensive drugs. Yet, not all patients are treated adequately, largely because of nonadherence, although drug ineffectiveness and counterbalancing mechanisms may also play a role. Novel antihypertensive drugs have not been introduced for at least one to two decades. Remarkably, over the last few years, a range of novel compounds is being introduced, acting either on novel targets, or displaying an exceptionally long half-life. The former may help to improve blood pressure lowering, for instance by interfering with counterbalancing mechanisms, while the latter might help to circumvent nonadherence. This review summarizes the latest developments, focusing on novel drugs acting on the endothelin system, the renin-angiotensin-aldosterone system (RAAS), and atrial natriuretic peptide (ANP).
No takes yet. Share an insight, caveat, or question.
Danser et al. (2025) conducted a review in Hypertension. Novel antihypertensive drugs (endothelin antagonists, angiotensinogen siRNA, aldosterone synthase inhibitors, ANP agonists) was evaluated. Novel antihypertensive drugs targeting the endothelin system, angiotensinogen, aldosterone synthase, and atrial natriuretic peptide offer promising strategies to overcome treatment resistance and nonadherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: